³ΙΘΛΏμΚΦ

header-logo
GettyImages-609179959-hero
headshot

Yu Fujiwara, MD

Assistant Professor

view provider profile

Locations

  • Froedtert Hospital
  • Clinical Cancer Center - Froedtert Hospital

Specialties

  • Medical Oncology

Languages

  • English, Japanese

New & Established Patients Call

Education

  • MD - Doctor of Medicine

Publications

  • (Gopalakrishnan D, Fujiwara Y, Collier KA, Park JJ, Zaemes JP, Lam ET, Alaklabi S, Jaeger EB, Barata PC, Kauffman EC, Atkins MB, Alva A, Yang Y, George S.) J Natl Compr Canc Netw. 2026 Oct 13:1-7 PMID: 42869085 10/13/2026

  • (Salgia NJ, Khan A, Fujiwara Y, Long M, Twoey GC, Leatt K, Chow J, Abrams SI, Schwaab T, Singh AK, Muhitch JB.) J Immunother Cancer. 2026 Oct 08;14(10) PMID: 42849919 PMCID: PMC13656130 10/08/2026

  • (Fujiwara Y, Kato S, Kurzrock R.) Hematol Oncol Clin North Am. 2026 Oct;40(5):685-704 PMID: 42686322 SCOPUS ID: 2-s2.0-105049040188 09/03/2026

  • (Fujiwara Y, Okamura Y, Ramesh M, Tehrani YF, Aburaki R, Takahashi T, Ahluwalia MS, Mukherjee S.) JNCI Cancer Spectr. 2026 Jul 07;10(4) PMID: 42316819 PMCID: PMC13375266 06/19/2026

  • (Markus A, Tsuchiya K, Takahashi T, MBBCh EE, Koseki M, Nishimura Y, Rohs NC, Fujiwara Y.) JNCI Cancer Spectr. 2026 Jul 07;10(4) PMID: 42234870 PMCID: PMC13428319 06/03/2026

  • (Ahmed J, Nishizaki D, Fujiwara Y, DePietro P, Jensen TJ, McFall T, Kato S, Kurzrock R.) ESMO Open. 2026 Jun;11(6):107768 PMID: 42263481 PMCID: PMC13272506 SCOPUS ID: 2-s2.0-105041408368 06/10/2026

  • (Marinelli D, Citarella F, Torchia A, Pannu S, Aijaz A, Sisca L, Russano M, Fujiwara Y, Takada K, Nassar AH, Banna GL, Ricciuti B, Brunetti L, Santo V, Passaro A, Saw SPL, Li MSC, Addeo A, Ferrara R, Di Maio M, Mountzios G, Santini D, Maugeri-Saccà M, Vincenzi B, Acker F, Reckamp KL, Cappuzzo F, Naqash AR, Cortellini A.) Cancer Treat Rev. 2026 Jun;147:103159 PMID: 42224849 06/02/2026

  • (Fujiwara Y, Takahashi T, Tsuchiya K, Koseki M, Markus A, Elias E, Nishimura Y, Puzanov I.) Target Oncol. 2026 May;21(3):327-336 PMID: 41996022 04/18/2026

  • (Fujiwara Y, Kato S, Nishizaki D, Miyashita H, Lee S, Jensen TJ, DePietro P, Seager RJ, Ikeda S, Kurzrock R.) NPJ Precis Oncol. 2026 Apr 28;10(1) PMID: 42049950 PMCID: PMC13328500 SCOPUS ID: 2-s2.0-105043594073 04/29/2026

  • (Low SK, Fujiwara Y, Nishizaki D, Kato S, Kurzrock R.) J Immunother Precis Oncol. 2026 Apr;9(2):36-45 PMID: 41994077 PMCID: PMC13078950 SCOPUS ID: 2-s2.0-105043493651 04/17/2026

  • (Yamada K, Matsui T, Takahashi T, Nishimura Y, Fujiwara Y.) Semin Arthritis Rheum. 2026 Apr;77:152938 PMID: 41643573 02/06/2026

  • (Paredes de la Fuente R, Karol AB, Markus A, Argulian A, Omori R, Fujiwara Y, Joshi H, Doroshow DB, Galsky MD.) JCO Glob Oncol. 2026 Feb;12:e2500411 PMID: 41719503 02/20/2026

Publications of from the

© 2026 ³ΙΘΛΏμΚΦ.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination, Anti-Harassment, and Legal Compliance Statement
The ³ΙΘΛΏμΚΦ (³ΙΘΛΏμΚΦ) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, military status, or other legally protected classification. ³ΙΘΛΏμΚΦ maintains full compliance with all applicable federal, state, and local laws and regulations in pursuit of our missions. Consistent with federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making.

³ΙΘΛΏμΚΦ's policies, federal and state laws, and regulations prohibit unlawful discrimination and harassment. Employees, learners, students, applicants, or other members of the ³ΙΘΛΏμΚΦ community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic.